查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1668150

嬰兒痙攣治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療類別、藥物類型、劑量、地區和競爭細分，2020-2030 年預測

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Drug Type, By Dosage, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球嬰兒痙攣治療市場價值為 1.4634 億美元，預計到 2030 年將達到 1.8194 億美元，複合年成長率為 3.67%。 全球嬰兒痙攣治療市場正在穩步成長，這得益於嬰兒痙攣症的持續上升， 全球嬰兒痙攣治療市場正在穩步成長，這得益於嬰兒痙攣的疾病。這種疾病也稱為韋斯特綜合症，由於其與發育遲緩和長期神經系統併發症有關，需要立即進行醫療干預。市場越來越注重早期診斷和干涉，醫療保健提供者強調識別突然、重複性痙攣等症狀的重要性。腦電圖（EEG）和神經影像等先進診斷工具的出現提高了檢測率，進一步刺激了對有效治療方案的需求。製藥公司和研究機構正在積極投資於可提高治療效果同時最大限度減少副作用的新型療法，從而促進市場的擴張。

市場概況
預測期 2026-2030
2024 年市場規模 1.4634 億美元
2030 年市場規模 1.8194億美元
2025-2030 年複合年成長率 3.67％
成長最快的領域 抗驚厥藥
最大的市場 北美洲

醫療保健專業人員和家長對嬰兒痙攣的認知不斷提高，對市場的成長起著至關重要的作用。隨著專科兒科神經病學中心的普及和醫療保健基礎設施的改善，患病嬰兒更容易得到及時治療。包括促腎上腺皮質激素 (ACTH)、氨己烯酸和皮質類固醇在內的標靶治療的開發顯著改善了患者的治療效果。企業不斷創新藥物配方，以提高療效，減少副作用。精準醫療和基因療法的應用正在獲得關注，為長期疾病管理帶來了希望。數位健康技術，包括遠距醫療和基於人工智慧（AI）的診斷工具，正在支援早期診斷和遠端患者監控，從而改善治療機會。然而，治療費用高昂且現有藥物的潛在副作用仍是主要挑戰，影響患者負擔能力和依從性。

兒科神經病學研究的進步正在為市場創造新的機遇，製藥公司正在與學術機構合作開發突破性的治療方法。新型藥物輸送機制的出現，包括緩釋製劑和鼻內療法，可望增強治療效果。政府不斷擴大的措施和對罕見疾病研究的資助正在加速藥物開發力度，鼓勵推出新的有效治療方案。患者權益團體和非營利組織在提高意識和為受影響家庭爭取經濟支持方面發揮著重要作用。基於生物標記的診斷技術與個人化醫療方法的整合將重新定義治療策略，為精準治療鋪路。儘管監管障礙和治療可及性有限等挑戰依然存在，但兒童癲癇領域的持續研究和創新預計將推動全球嬰兒痙攣治療市場的持續成長。

主要市場促進因素

診斷技術的進步

主要市場挑戰

認知和診斷有限

主要市場趨勢

基因療法

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球嬰兒痙攣治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類別（抗驚厥藥、皮質類固醇、其他）
    • 依藥物類型（維加巴特林、促腎上腺皮質激素、其他）
    • 按劑量（固體、液體）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：亞太地區嬰兒痙攣治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章：歐洲嬰兒痙攣治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美嬰兒痙攣治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 9 章：南美洲嬰兒痙攣治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲嬰兒痙攣治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球嬰兒痙攣治療市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • Merck KGaA
  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • Johnson & Johnson
  • Abbott Laboratories Inc
  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc.
  • AstraZeneca PLC
  • GSK PLC

第 17 章：策略建議

第18章 關於出版商,免責事項

簡介目錄
Product Code: 18993

Global Infantile Spasms Therapeutics Market was valued at USD 146.34 Million in 2024 and is expected to reach USD 181.94 Million in the forecast period with a CAGR of 3.67% through 2030. The Global Infantile Spasms Therapeutics Market is witnessing steady growth, driven by the increasing prevalence of infantile spasms, a rare yet severe form of epilepsy that primarily affects infants under one year of age. The condition, also known as West syndrome, requires immediate medical intervention due to its association with developmental delays and long-term neurological complications. The market is characterized by a growing focus on early diagnosis and intervention, with healthcare providers emphasizing the importance of recognizing symptoms such as sudden, repetitive spasms. The availability of advanced diagnostic tools, including electroencephalograms (EEG) and neuroimaging, has improved detection rates, further fueling demand for effective treatment options. Pharmaceutical companies and research institutions are actively investing in novel therapies that enhance treatment efficacy while minimizing adverse effects, contributing to the market's expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 146.34 Million
Market Size 2030USD 181.94 Million
CAGR 2025-20303.67%
Fastest Growing SegmentAnticonvulsants
Largest MarketNorth America

Rising awareness among healthcare professionals and parents about infantile spasms is playing a crucial role in the market's growth. Increased access to specialized pediatric neurology centers and improvements in healthcare infrastructure have made it easier for affected infants to receive timely treatment. The development of targeted therapeutics, including adrenocorticotropic hormone (ACTH), vigabatrin, and corticosteroids, has significantly improved patient outcomes. Companies are continuously innovating drug formulations to enhance efficacy and reduce side effects. The adoption of precision medicine and gene-based therapies is gaining traction, providing hope for long-term disease management. Digital health technologies, including telemedicine and artificial intelligence (AI)-based diagnostic tools, are supporting early diagnosis and remote patient monitoring, leading to improved treatment access. However, the high cost of treatment and the potential side effects of existing medications remain key challenges, impacting affordability and patient adherence.

Advancements in pediatric neurology research are creating new opportunities in the market, with pharmaceutical companies collaborating with academic institutions to develop breakthrough treatments. The emergence of novel drug delivery mechanisms, including sustained-release formulations and intranasal therapies, is expected to enhance therapeutic outcomes. Expanding government initiatives and funding for rare disease research are accelerating drug development efforts, encouraging the launch of new and effective treatment options. Patient advocacy groups and non-profit organizations are playing a significant role in raising awareness and securing financial support for affected families. The integration of biomarker-based diagnostic techniques and personalized medicine approaches is set to redefine treatment strategies, paving the way for precision-based therapies. While challenges such as regulatory hurdles and limited treatment accessibility persist, continued research and innovation in the field of pediatric epilepsy are expected to drive sustained growth in the Global Infantile Spasms Therapeutics Market.

Key Market Drivers

Advancements in Diagnostic Techniques

Infantile spasms, a rare and severe form of epilepsy predominantly affecting infants during their first year, can have devastating consequences if left untreated. Timely and accurate diagnosis is crucial for effective management, and advancements in diagnostic techniques are significantly enhancing the global infantile spasms therapeutics market.

The incidence of infantile spasms is approximately 1 in 2,920 live births. These seizures often manifest as brief, repetitive muscle contractions, which can be mistaken for normal infant movements, leading to potential delays in diagnosis. A critical diagnostic tool is the electroencephalogram (EEG), which measures brain electrical activity. Interpreting EEG findings requires expertise, as patterns associated with infantile spasms can be subtle and easily overlooked.

Innovations in neuroimaging techniques, such as magnetic resonance imaging (MRI), have enabled healthcare providers to visualize the brain with greater clarity, identifying structural abnormalities associated with infantile spasms. Studies indicate that MRI can detect abnormalities in approximately 50% to 66% of affected children. Continuous video EEG monitoring has also revolutionized diagnosis by combining real-time video with EEG data, offering a comprehensive view of the infant's symptoms and brain activity, thus facilitating more accurate and timely diagnoses.

Key Market Challenges

Limited Awareness and Diagnosis

Limited awareness and diagnosis of infantile spasms present a significant challenge in the global infantile spasms therapeutics market. Infantile spasms are a rare but severe form of epilepsy that require immediate medical intervention to prevent long-term neurological complications. However, many parents, caregivers, and even healthcare professionals may not be fully aware of the early symptoms, leading to delayed diagnosis and treatment. The subtle nature of infantile spasms, often resembling normal baby movements or minor startles, makes it difficult for parents to recognize them as a serious neurological condition. This lack of awareness results in delayed medical consultations, which can significantly impact treatment outcomes and the long-term cognitive development of affected infants.

Healthcare professionals, particularly in regions with limited neurological expertise, may also struggle with early detection. Infantile spasms are often misdiagnosed as colic, reflux, or benign myoclonic movements, delaying the administration of appropriate therapies. Limited access to advanced diagnostic tools, such as video EEG monitoring, in rural and underdeveloped areas further exacerbates the problem. Early and accurate diagnosis is critical because timely intervention with adrenocorticotropic hormone (ACTH), vigabatrin, or corticosteroids has been shown to improve seizure control and neurodevelopmental outcomes.

Key Market Trends

Gene Therapies

Gene therapies are emerging as a transformative trend in the global infantile spasms therapeutics market, offering the potential for long-term disease modification rather than symptomatic relief. Infantile spasms, a rare and severe form of epilepsy, are often linked to genetic mutations, particularly in genes such as ARX, CDKL5, STXBP1, and TSC1/TSC2. Advances in gene-editing technologies, including CRISPR-Cas9 and adeno-associated virus (AAV)-based gene delivery systems, are enabling researchers to develop targeted therapies that address the underlying genetic causes of the condition. Unlike conventional treatments such as adrenocorticotropic hormone (ACTH) and vigabatrin, which primarily aim to control seizures, gene therapies hold promise in halting or reversing disease progression at a molecular level.

Ongoing research efforts are focused on developing precise gene-editing and replacement therapies to restore normal neuronal function in affected infants. Preclinical studies have shown promising results in modifying defective genes associated with infantile spasms, potentially leading to lasting therapeutic benefits. Pharmaceutical and biotechnology companies are investing in gene therapy programs, with several candidates progressing through early-stage clinical trials. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are providing support for orphan drug designation and expedited approval pathways for gene therapies targeting rare pediatric neurological disorders.

Despite the high cost and complexity of gene therapy development, advancements in delivery mechanisms and manufacturing processes are expected to improve accessibility over time. The growing collaboration between academic research institutions and biotech firms is accelerating the translation of gene therapies from the laboratory to clinical applications. As the understanding of the genetic basis of infantile spasms continues to expand, gene therapies have the potential to redefine the standard of care, offering a durable and potentially curative treatment option for patients who do not respond to conventional therapies. The market is witnessing an increasing shift towards personalized medicine, reinforcing the role of gene therapies in the future of infantile spasms treatment.

Key Market Players

  • Merck KGaA
  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • Johnson & Johnson
  • Abbott Laboratories Inc
  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc.
  • AstraZeneca PLC
  • GSK PLC

Report Scope:

In this report, the Global Infantile Spasms Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infantile Spasms Therapeutics Market, By Therapeutic Class:

  • Anticonvulsants
  • Corticosteroids
  • Others

Infantile Spasms Therapeutics Market, By Drug Type:

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others

Infantile Spasms Therapeutics Market, By Dosage:

  • Solid
  • Liquid

Infantile Spasms Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infantile Spasms Therapeutics Market.

Available Customizations:

Global Infantile Spasms Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Applications
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infantile Spasms Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Class (Anticonvulsants, Corticosteroids, Others)
    • 5.2.2. By Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Others)
    • 5.2.3. By Dosage (Solid, Liquid)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Infantile Spasms Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Class
    • 6.2.2. By Drug Type
    • 6.2.3. By Dosage
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Infantile Spasms Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Class
        • 6.3.1.2.2. By Drug Type
        • 6.3.1.2.3. By Dosage
    • 6.3.2. India Infantile Spasms Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Class
        • 6.3.2.2.2. By Drug Type
        • 6.3.2.2.3. By Dosage
    • 6.3.3. Australia Infantile Spasms Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Class
        • 6.3.3.2.2. By Drug Type
        • 6.3.3.2.3. By Dosage
    • 6.3.4. Japan Infantile Spasms Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Therapeutic Class
        • 6.3.4.2.2. By Drug Type
        • 6.3.4.2.3. By Dosage
    • 6.3.5. South Korea Infantile Spasms Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Therapeutic Class
        • 6.3.5.2.2. By Drug Type
        • 6.3.5.2.3. By Dosage

7. Europe Infantile Spasms Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Class
    • 7.2.2. By Drug Type
    • 7.2.3. By Dosage
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Infantile Spasms Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Class
        • 7.3.1.2.2. By Drug Type
        • 7.3.1.2.3. By Dosage
    • 7.3.2. Germany Infantile Spasms Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Class
        • 7.3.2.2.2. By Drug Type
        • 7.3.2.2.3. By Dosage
    • 7.3.3. Spain Infantile Spasms Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Class
        • 7.3.3.2.2. By Drug Type
        • 7.3.3.2.3. By Dosage
    • 7.3.4. Italy Infantile Spasms Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Class
        • 7.3.4.2.2. By Drug Type
        • 7.3.4.2.3. By Dosage
    • 7.3.5. United Kingdom Infantile Spasms Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Class
        • 7.3.5.2.2. By Drug Type
        • 7.3.5.2.3. By Dosage

8. North America Infantile Spasms Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Class
    • 8.2.2. By Drug Type
    • 8.2.3. By Dosage
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Infantile Spasms Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Class
        • 8.3.1.2.2. By Drug Type
        • 8.3.1.2.3. By Dosage
    • 8.3.2. Mexico Infantile Spasms Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Class
        • 8.3.2.2.2. By Drug Type
        • 8.3.2.2.3. By Dosage
    • 8.3.3. Canada Infantile Spasms Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Class
        • 8.3.3.2.2. By Drug Type
        • 8.3.3.2.3. By Dosage

9. South America Infantile Spasms Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Class
    • 9.2.2. By Drug Type
    • 9.2.3. By Dosage
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Infantile Spasms Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Class
        • 9.3.1.2.2. By Drug Type
        • 9.3.1.2.3. By Dosage
    • 9.3.2. Argentina Infantile Spasms Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Class
        • 9.3.2.2.2. By Drug Type
        • 9.3.2.2.3. By Dosage
    • 9.3.3. Colombia Infantile Spasms Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Class
        • 9.3.3.2.2. By Drug Type
        • 9.3.3.2.3. By Dosage

10. Middle East and Africa Infantile Spasms Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Class
    • 10.2.2. By Drug Type
    • 10.2.3. By Dosage
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Infantile Spasms Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Class
        • 10.3.1.2.2. By Drug Type
        • 10.3.1.2.3. By Dosage
    • 10.3.2. Saudi Arabia Infantile Spasms Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Class
        • 10.3.2.2.2. By Drug Type
        • 10.3.2.2.3. By Dosage
    • 10.3.3. UAE Infantile Spasms Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Class
        • 10.3.3.2.2. By Drug Type
        • 10.3.3.2.3. By Dosage

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Infantile Spasms Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Merck KGaA
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
  • 16.2. Novartis AG
  • 16.3. Sanofi SA
  • 16.4. Pfizer Inc
  • 16.5. Johnson & Johnson
  • 16.6. Abbott Laboratories Inc
  • 16.7. Teva Pharmaceutical Industries Ltd
  • 16.8. Bausch Health Companies Inc.
  • 16.9. AstraZeneca PLC
  • 16.10. GSK PLC

17. Strategic Recommendations

18. About Us & Disclaimer